FIG. 1A

Anti-GDF-8 antibody variable heavy (VH) region amino acid alignments

Murine VH	1	EVQLVESGGGLVKPGGSLKLSCAASGFTFS**SYAMS**WVRQT	40	(SEQ ID NO:3)
DP-47	1	EVQLLESGGGLVQPGGSLRLSCAASGFTFS**SYAMS**WVRQA	40	(SEQ ID NO:33)
Humanized VH0	1	EVQLLESGGGLVQPGGSLRLSCAASGFTFS**SYAMS**WVRQA	40	(SEQ ID NO:44)
Humanized VH1	1	EVQLLESGGGLVQPGGSLRLSCAASGFTFS**SYAMS**WVRQA	40	(SEQ ID NO:7)
Humanized VH2	1	EVQLLESGGGLVQPGGSLRLSCAASGFTFS**SYAMS**WVRQA	40	(SEQ ID NO:66)
Humanized VH3	1	EVQLLESGGGLVQPGGSLRLSCAASGFTFS**SYAMS**WVRQA	40	(SEQ ID NO:68)
Humanized VH4	1	EVQLLESGGGLVQPGGSLRLSCAASGFTFS**SYAMS**WVRQA	40	(SEQ ID NO:70)
Humanized VH5	1	EVQLLESGGGLVQPGGSLRLSCAASGFTFS**SYAMS**WVRQA	40	(SEQ ID NO:72)
Murine VH	41	PEKRLEWVA**TISSGGSYTSYPDSVKG**RFTISRDNAKNTLY	80	(SEQ ID NO:3)
DP-47	41	PGKGLEWVS**AISGSGGSTYYADSVKG**RFTISRDNSKNTLY	80	(SEQ ID NO:33)
Humanized VH0	41	PGKGLEWVS**TISSGGSYTSYPDSVKG**RFTISRDNSKNTLY	80	(SEQ ID NO:44)
Humanized VH1	41	PGKGLEWVS**TISSGGSYTSYPDSVKG**RFTISRDNSKNTLY	80	(SEQ ID NO:7)
Humanized VH2	41	PGKGLEWVS**AISGSGGSTYYADSVKG**RFTISRDNSKNTLY	80	(SEQ ID NO:66)
Humanized VH3	41	PGKGLEWVS**AISSSGGYTYYADSVKG**RFTISRDNSKNTLY	80	(SEQ ID NO:68)
Humanized VH4	41	PGKGLEWVS**TISSGGSYTSYPDSVKG**RFTISRDNSKNTLY	80	(SEQ ID NO:70)
Humanized VH5	41	PGKGLEWVS**TISSSGSYTSYPDSVKG**RFTISRDNSKNTLY	80	(SEQ ID NO:72)
		*		
Murine VH	81	LQMSSLRSEDTAMYYCAR**QDYAMNY**WGQGT**S**VTVSS	116	(SEQ ID NO:3)
DP-47	81	LQMNSLRAEDTAVYYCAK	98	(SEQ ID NO:33)
Humanized VH0	81	LQMNSLRAEDTAVYYCAK**QDYAMNY**WGQGT**L**VTVSS	116	(SEQ ID NO:44)
Humanized VH1	81	LQMNSLRAEDTAVYYCAK**QDYAMNY**WGQGT**M**VTVSS	116	(SEQ ID NO:7)
Humanized VH2	81	LQMNSLRAEDTAVYYCAK**QDYAMNY**WGQGT**L**VTVSS	116	(SEQ ID NO:66)
Humanized VH3	81	LQMNSLRAEDTAVYYCAK**QDYAMNY**WGQGT**L**VTVSS	116	(SEQ ID NO:68)
Humanized VH4	81	LQMNSLRAEDTAVYYCAK**QDYAFDY**WGQGT**L**VTVSS	116	(SEQ ID NO:70)
Humanized VH5	81	LQMNSLRAEDTAVYYCAK**QDYAMNY**WGQGT**L**VTVSS	116	(SEQ ID NO:72)

FIG. 1B

Antibody variable light (VL) region amino acid alignments

```
Murine VL       1  DIEMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKP 40 (SEQ ID NO:5)
DPK-9           1  DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKP 40 (SEQ ID NO:32)
Humanized VL0   1  DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKP 40 (SEQ ID NO:46)
Humanized VL1   1  DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKP 40 (SEQ ID NO:9)
Humanized VL2   1  DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKP 40 (SEQ ID NO:67)
Humanized VL3   1  DIQMTQSPSSLSASVGDRVTITCRASQSISTALNWYQQKP 40 (SEQ ID NO:69)
Humanized VL4   1  DIQMTQSPSSLSASVGDRVTITCRASQSISTALNWYQQKP 40 (SEQ ID NO:71)
Humanized VL5   1  DIQMTQSPSSLSASVGDRVTITCRASQSISTALNWYQQKP 40 (SEQ ID NO:73)

Murine VL      41 GQSPKLLLYSASYRYTGVPDRFTGSGSGTDFTFTISSVQA 80 (SEQ ID NO:5)
DPK-9          41 GKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQP 80 (SEQ ID NO:32)
Humanized VL0  41 GKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQP 80 (SEQ ID NO:46)
Humanized VL1  41 GKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQP 80 (SEQ ID NO:9)
Humanized VL2  41 GKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQP 80 (SEQ ID NO:67)
Humanized VL3  41 GKAPKLLIYSASSLQSGVPSRFSGSGSGTDFTLTISSLQP 80 (SEQ ID NO:69)
Humanized VL4  41 GKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQP 80 (SEQ ID NO:71)
Humanized VL5  41 GKAPKLLIYSASSLQSGVPSRFSGSGSGTDFTLTISSLQP 80 (SEQ ID NO:73)
                                  *
Murine VL      81 EDLAVYYCQQHYSTPWTFGGGTKLEIK      107 (SEQ ID NO:5)
DPK-9          81 EDFATYYCQQSYSTP                  95 (SEQ ID NO:32)
Humanized VL0  81 EDFATYYCQQHYSTPWTFGGGTKVEIK    107 (SEQ ID NO:46)
Humanized VL1  81 EDFATYYCQQHYSTPWTFGQGTKVEIK    107 (SEQ ID NO:9)
Humanized VL2  81 EDFATYYCQQHYSTPWTFGGGTKVEIK    107 (SEQ ID NO:67)
Humanized VL3  81 EDFATYYCQQSYSTPWTFGGGTKVEIK    107 (SEQ ID NO:69)
Humanized VL4  81 EDFATYYCQQSYSTPWTFGGGTKVEIK    107 (SEQ ID NO:71)
Humanized VL5  81 EDFATYYCQQSYSTPLTFGGGTKVEIK    107 (SEQ ID NO:73)
```

FIG. 2A



300
250
200
150
100
50
0
Muscle Mass (mg)
Control
Antibody
GAS
QUAD

FIG. 2B



Percent Increase Muscle Mass
Versus Control
20
15
10
5
0
GAS
QUAD
EDL

FIG. 3




FIG. 4A




FIG. 4B




FIG. 5A



Total Mass (g)
21
20
19
18
17
16
15
14
0
0 7 14 21 28
Vehicle
0 7 14 21 28
0.3 mg/kg
0 7 14 21 28
1 mg/kg
0 7 14 21 28
3 mg/kg
0 7 14 21 28
10 mg/kg
0 7 14 21 28
30 mg/kg

FIG. 5B



Change in Lean Mass (g)
3
2
1
0
Vehicle
0.3 mg/kg
1.0 mg/kg
3.0 mg/kg
10 mg/kg
30 mg/kg

FIG. 6A




FIG. 6B



160
150
140
130
120
110
100
0
Grip Strength (N)
Vehicle
Antibody

FIG. 7A



Vehicle
Antibody
Muscle Mass (mg)
400
300
200
100
0
MDX GAS
MDX QUAD
C57Bl/6 GAS
C57Bl/6 QUAD

FIG. 7B



Percent Increase Muscle Mass
Versus Control
14
12
10
8
6
4
2
0
MDX
GAS
MDX
QUAD

FIG. 8



Total Lean Mass
Leg Lean Mass
Percent Change in Lean Mass
0
2
4
6
8
10
12
Vehicle
3 mg/kg
10 mg/kg
30 mg/kg

FIG. 9




FIG. 10A




FIG. 10B



Percent Change Muscle Volume
20
15
10
5
0
Vehicle
10 mg/kg
30 mg/kg

FIG. 11




FIG. 12A

Anti-GDF-8 antibody OGD1.0.0 heavy chain (SEQ ID NO:58) containing VH0 VH region

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVST ISSGGSYTSY  60
PDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKQD YAMNYWGQGT LVTVSSASTK 120
GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS 180
LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PEAAGAPSVF 240
LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN 360
QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN 420
VFSCSVMHEA LHNHYTQKSL SLSPGK
```

FIG. 12B

Anti-GDF-8 antibody OGD1.0.0 light chain (SEQ ID NO:59) containing VL0 VL region

```
DIQMTQSPSS LSASVGDRVT ITCKASQDVS TAVAWYQQKP GKAPKLLIYS ASYRYTGVPS  60
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYSTPWTFGG GTKVEIKRTV AAPSVFIFPP 120
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT 180
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
```